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Background: Due to the pleiotropic effects of nitric oxide (NO) within the lungs, it is likely that NO is a significant
factor in the pathogenesis of chronic obstructive pulmonary disease (COPD). The aim of this study was to test for
association between single nucleotide polymorphisms (SNPs) in three NO synthase (NOS) genes and lung function,
as well as to examine gene expression and protein levels in relation to the genetic variation.
Methods: One SNP in each NOS gene (neuronal NOS (NOS1), inducible NOS (NOS2), and endothelial NOS (NOS3))
was genotyped in the Lung Health Study (LHS) and correlated with lung function. One SNP (rs1800779) was also
analyzed for association with COPD and lung function in four COPD case–control populations. Lung tissue
expression of NOS3 mRNA and protein was tested in individuals of known genotype for rs1800779.
Immunohistochemistry of lung tissue was used to localize NOS3 expression.
Results: For the NOS3 rs1800779 SNP, the baseline forced expiratory volume in one second in the LHS was
significantly higher in the combined AG + GG genotypic groups compared with the AA genotypic group. Gene
expression and protein levels in lung tissue were significantly lower in subjects with the AG + GG genotypes than in
AA subjects. NOS3 protein was expressed in the airway epithelium and subjects with the AA genotype
demonstrated higher NOS3 expression compared with AG and GG individuals. However, we were not able to
replicate the associations with COPD or lung function in the other COPD study groups.
Conclusions: Variants in the NOS genes were not associated with lung function or COPD status. However, the G
allele of rs1800779 resulted in a decrease of NOS3 gene expression and protein levels and this has implications for
the numerous disease states that have been associated with this polymorphism.
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Nitric oxide (NO) is a molecule that is involved in many
physiological and pathological pathways and can have
either beneficial or detrimental effects. Many studies
have shown that NO has protective effects on human
airways such as muscle relaxation, attenuation of airway
hyper-responsiveness to bronchoconstrictor stimuli, and
the killing of invading microorganisms [1]. In contrast,* Correspondence: andrew.sandford@hli.ubc.ca
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distribution, and reproduction in any mediumadverse effects of NO have also been observed, such as
vasodilation of the bronchial circulation, increased airway
secretions and the promotion of pro-inflammatory path-
ways, as well as necrosis and apoptosis [1].
Endogenous NO is primarily synthesized by enzymes
known as NO synthases (NOS) which catalyze the cellular
production of NO from arginine. There are three known
NOS isoforms: neuronal NOS (NOS1), inducible NOS
(NOS2), and endothelial NOS (NOS3). In humans, NOS1
can be found in neurons and endothelial cells in the lung
[2], while NOS3 is found in bronchiolar epithelial cells
and the endothelium [3,4]. NOS2 is expressed in thetral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Characteristics of the 4132 Lung Health Study
participants (2611 male, 1521 female)
Characteristic Total
Age (mean ± SD), years 48.5 ± 6.7
Smoking history (mean ± SD), pack-yearsa 40.4 ± 18.4
Baseline FEV1 post-bronchodilator
(mean ± SD), % predictedb
78.55 ± 9.10
FEV1 post-bronchodilator rate of decline
(mean ± SD), % predicted / yearc
−0.97 ± 1.78
aNumber packs of cigarettes smoked per day × number of years of smoking.
bLung function at the start of the study measured as forced expiratory volume
in 1 second (FEV1).
cChange in lung function over a five-year period measured as forced expira-
tory volume in 1 second (FEV1).
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alveolar macrophages [2].
Due to its pleiotropic effects, it is likely that NO is a
significant factor in the pathogenesis of lung diseases such
as chronic obstructive pulmonary disease (COPD), which
is characterized by airflow limitation that is not fully
reversible. There is evidence to suggest that NOS genes
are associated with COPD. Recently, the mRNA and
protein expression of NOS1 and NOS2 were observed
to be increased in the peripheral lung tissue of smokers
with COPD compared with nonsmoker controls, whereas
the opposite effect was detected for NOS3 expression [6].
Another study reported that the numbers of NOS2+ and
NOS3+ cells were increased in the bronchial submucosa
of smokers with COPD compared with nonsmoker controls
[7]. Furthermore, deficiency of NOS2 has been shown to be
protective against cigarette smoke-induced emphysema in a
mouse model [8].
To further determine the effects of NOS in COPD,
it is important to determine whether single nucleotide
polymorphisms (SNPs) in NOS genes are associated with
phenotypes related to the disease. It has been widely
acknowledged that genetic factors account for some of
the variability of lung function among smokers [9,10],
suggesting an interaction between genetic and environ-
mental influences on disease progression. The aim of this
study was to determine whether NOS gene variants were
associated with phenotypes related to COPD. We examined
the rate of decline of lung function and baseline lung func-
tion in smokers with mild to moderate airflow obstruction
from the Lung Health Study (LHS) in relation to polymor-
phisms in three NOS genes. The LHS was a randomized
trial of an anti-smoking intervention and bronchodilator
treatment in volunteer smokers [11]. We selected polymor-
phisms in NOS genes that had previously been associated
with gene function or COPD-related traits [12-14]. We
sought to determine whether these polymorphisms were
associated with lung function decline and baseline level in
COPD patients in the LHS as well as with COPD and lung
function in four replication case–control sets.
Methods
Ethics statement
The investigation of the LHS and lung tissue samples was
approved by the University of British Columbia/Providence
Health Care Research Ethics Board and all subjects
provided written informed consent. We attempted to
replicate the associations in subjects from the following
previously recruited populations: Norway COPD Cohort
(GenKOLS) [15], National Emphysema Treatment Trial
(NETT) [16,17], Normative Aging Study (NAS) [18],
Evaluation of COPD Longitudinally to Identify Predictive
Surrogate Endpoints (ECLIPSE) [19] and COPDGene [20].
These studies were approved by the relevant institutionalreview boards and all subjects provided written informed
consent. For the NAS, anonymized data were used, as
approved by the institutional review boards of Partners
Healthcare System and the Boston VA.
Study participants
The participants in the primary analysis were from the
National Heart, Lung, and Blood Institute sponsored LHS
cohort [11], consisting of smokers who had mild/moderate
lung function impairment at the start of the study. Table 1
provides the characteristics of the LHS participants. Of the
5887 total participants in the LHS cohort, 4132 individuals
of Caucasian descent had DNA samples available for the
study. Lung function at the start of the study was expressed
as forced expiratory volume in 1 second (FEV1) as a per-
centage of predicted value. The change in lung function,
measured as change in FEV1 % predicted per year over a
five-year period, was also an outcome measure of this
study. For gene expression in lung tissue, genomic DNA,
mRNA and protein were isolated from lung tissue from
Caucasian patients who had undergone lobar or lung
resection surgery for a localized lung cancer (n = 27).
These samples were obtained from the James Hogg Re-
search Centre Lung Registry. SNPs that showed association
with lung function in the LHS cohort were genotyped in
four Caucasian case–control cohorts: 1) the first 1000
COPDGene study subjects, 2) the COPD cases and smok-
ing controls of the ECLIPSE study, 3) the NETT cases and
NAS controls, and 4) the GenKOLS case–control popula-
tion from Norway (Table 2) as described previously [21].
Gene variants and genotyping
SNP selection was based on previous genetic associations
with disease and function (Table 3). The NOS1 SNP
(rs41279104) is located in the exon 1c regulatory region.
Both the NOS2 SNP (rs8078340) and the NOS3 SNP
(rs1800779) are located in their respective promoter re-
gions. DNA from blood samples of the LHS participants
was whole genome amplified using the REPLI-g Mini Kit
(Qiagen, Mississauga, ON, Canada) prior to genotyping.
Table 2 Characteristics of the case–control replication study groups
Characteristic COPDGene ECLIPSE NETT/NAS GenKOLS
Cases Controls Cases Controls Cases Controls Cases Controls
Number of participants 499 501 1764 178 373 435 863 808
Age (mean ± SD), years 64.77 ± 8.12 60.20 ± 8.66 63.63 ± 7.10 57.48 ± 9.44 67.47 ± 5.78 69.8 ± 7.49 65.53 ± 10.03 55.62 ± 9.71
Smoking history (mean ± SD),
pack-yearsa
54.76 ± 26.69 38.87 ± 21.07 50.29 ± 27.42 32.11 ± 24.84 66.43 ± 30.68 40.66 ± 27.85 31.98 ± 18.46 19.66 ± 13.58
FEV1 (mean ± SD),
% predictedb
48.73 ± 18.41 97.98 ± 11.32 47.63 ± 15.62 107.83 ± 13.56 28.12 ± 7.38 99.97 ± 13.20 50.63 ± 17.44 94.91 ± 9.24
Sex (% male) 49.5% 50.1% 67.0% 57.9% 63.8% 100% 60.1% 50.1%
aNumber packs of cigarettes smoked per day × number of years of smoking.
bLung function was measured as forced expiratory volume in 1 second (FEV1) as a percentage of the predicted value.
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City, CA, USA) were used: assay ID for rs41279104 =C__
86363451_10; rs8078340 =C__29024700_10; rs1800779 =
C__7599687_1. For each assay, 5 ng of DNA was used for
allelic discrimination. For genome-wide SNP genotyping
in the COPDGene, ECLIPSE, NETT-NAS, and GenKOLS
populations, all cohorts were genotyped on Illumina
platforms (Human Hap550, Quad610, and Omni1 Quad).
Quality control in each cohort included subject miss-
ingness, discordances, relatedness, and sex; and marker
missingness, discordances, singletons, and Hardy-Weinberg
equilibrium.
Quantitative polymerase chain reaction (PCR)
RNA was extracted from lung tissue samples using the
RNeasy Mini Kit (Qiagen) and cDNA was synthesized
using SuperScript®III Reverse Transcriptase (Life Tech-
nologies, Grand Island, NY, USA). The cDNA samples
were used to determine the gene expression of NOS3. The
reference gene used was GNB2L1 as this was previously
shown to be stably expressed in lung tissue [22]. Gene
expression assays for NOS3 (Hs01574659_m1) and GNB2L1
(Hs00272002_m1) were purchased from Applied Bio-
systems. Gene expression was calculated using cycle
threshold (CT) values for NOS3 and GNB2L1, as previously
described [23].
Protein expression levels
Human lung tissue fragments (30 mg) were homogenized
in protein extraction buffer with protease and phosphatase
inhibitors (Sigma-Aldrich, St. Louis, MO, USA). Protein
lysates were resolved by SDS-PAGE and transferred to
nitrocellulose membranes, and probed with anti NOS3Table 3 Description of the polymorphisms studied
Gene SNP Protein Allele change L
NOS1 rs41279104 Neuronal NOS C = > T P
NOS2 rs8078340 Inducible NOS G = > A P
NOS3 rs1800779 Endothelial NOS A = > G Inrabbit polyclonal antibody NOS3 (C-20): sc-654 at a
concentration of 200 μg/mL (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA) and anti-β-tubulin monoclo-
nal antibody clone AA2 at a concentration of 1 mg/mL
(Upstate Co., Lake Placid, NY, USA). Detection was
performed with IR700 and IR800 anti-mouse and anti-
rabbit antibodies (Cell Signaling Technology, Danvers,
MA, USA). The density of the bands was analyzed with the
Odyssey Infrared Imaging System (LI-COR Biotechnology,
Lincoln, NE, USA) using two infrared channels inde-
pendently. The results were expressed as NOS3 / β-tubulin
density ratios.Immunohistochemistry
Sections were de-paraffinized, rehydrated, and antigen re-
trieved by autoclaving (15 min, 120°C, 30 psi) for 20 min
in citrate target retrieval solution (Dako, Mississauga, ON,
Canada). Endogenous peroxidase was quenched with 3%
H2O2 and non-specific interactions blocked for 20 min
with 10% goat serum. Antibody directed against human
NOS3 (NOS3 (C-20): sc-654, Santa Cruz Biotechnology,
Inc.) at 200 μg/mL was added overnight at 4°C in 5% goat
serum. Sections were then incubated with biotinylated
goat anti-mouse (1:100, Vector Labs Burlingame, CA,
USA) for 60 min followed by a 10 min treatment with
Streptavidin-HRP (Dako). The NOS3 antigen was visualized
using the brown chromogen 3, 3-diaminobenzidine (Dako)
and counterstained with Harris Hematoxylin Solution
(Sigma-Aldrich). Finally, sections were then dehydrated
and mounted with Cytoseal 60 (Richard-Allan Scientific,
Kalamazoo, MI, USA). Antibody dilutions and all washes
were in TRIS-buffered saline solution.ocation Association
romoter for exon 1c Reduced gene expression [12]
romoter region Decreased DNA-protein complex [13]
tronic Lower FEV1 % predicted in COPD patients [14]
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The JMP 5.1 statistical software package (SAS Institute
Inc., Cary, NC, USA) was used for analysis of the rela-
tionship between the genetic variants and the measures
of lung function in the LHS. Agreement of the genotype
distributions with Hardy-Weinberg equilibrium was
assessed using a X2 goodness-of-fit analysis. The two
outcomes used in the LHS were baseline and rate of de-
cline of post-bronchodilator FEV1, expressed as a percent
of predicted value. Statistical analyses were performed by
multiple linear regression. For the COPDGene, ECLIPSE,
NETT-NAS, and GenKOLS, after removal of principal
component outliers, genotype imputation within each study
was performed using MaCH and CEU samples from
HapMap2 and the 1000 Genomes Project as a reference
population. Association analysis of SNPs with case–
control status was performed in each cohort using logistic
regression, adjusting for age, pack-years of cigarette
smoking, and genetic ancestry using PLINK 1.07. Results
were combined among the four cohorts using fixed effect
meta-analyses using METAL and R 2.12 (manuscript
submitted). Differences in gene expression and protein
levels between the three genotypes were assessed using
two-tailed t-tests.
Results
Allelic discrimination in the lung health study
None of the three SNPs were in Hardy-Weinberg equilib-
rium for their genotypic distributions in the Caucasian
LHS population (rs41279104, p-value = 0.04; rs8078340,
p-value = 0.008; rs1800779, p = 0.003). We did not detect
any association of either the rs41279104 or the rs8078340
polymorphisms with baseline FEV1 or rate of decline of
FEV1 (Table 4). However, there was an association of the
rs1800779 SNP with baseline lung function (p = 0.0018)
(Table 4). This result remained significant (p = 0.0108)Table 4 Genotype frequencies of NOS polymorphisms among
with lung function
Gene SNP Genotype N Mean ± SE
Baseline FEV1
(% predicted)
p-value*a
NOS1 rs41279104 CC 2650 (79%) 78.39 ± 0.17 Referent
CT 650(19%) 78.84 ± 0.37 0.7688
TT 55 (2%) 79.33 ± 1.19 0.3825
NOS2 rs8078340 GG 2760 (76%) 78.64 ± 0.17 Referent
AG 794 (22%) 78.28 ± 0.32 0.7166
AA 81 (2%) 77.82 ± 1.00 0.2977
NOS3 rs1800779 AA 1448 (41%) 77.97 ± 0.24 Referent
AG 1552 (44%) 78.81 ± 0.23 0.8034
GG 516 (15%) 79.31 ± 0.39 0.0273
*p-values were adjusted for age, sex, and smoking history (pack-years).
ap-value for comparison to the wild type homozygous genotype.
bp-value for the additive model.after Bonferroni correction for multiple comparisons
(3 SNPs and 2 outcomes). In particular, subjects with the
GG genotype had higher baseline FEV1 compared with sub-
jects who had the AA genotype (p = 0.0273). Furthermore,
with the AG+GG genotypes combined, an association with
an increase in baseline FEV1 was observed compared with
the AA genotype (p = 0.0042). No significant association,
however, was observed with rate of decline of FEV1. An
association study of this SNP was then performed in the
four replication case–control populations; however no
significant findings were observed (Table 5). In addition,
we examined the relationship of rs1800779 to FEV1 %
predicted in the four replication populations but there was
no significant association with lung function in either the
cases or the controls (Table 6).
NOS3 mRNA expression in lung tissue
Since we had observed an association between the NOS3
rs1800779 polymorphism and lung function levels in the
LHS, a follow-up experiment was performed to determine
the effect of rs1800779 on NOS3 gene expression in lung
tissue. Individuals were closely matched for age and sex
among each genotype (7 males and 2 females for each
genotype; average age 60 ± 6 years in all 3 groups). Of the
subjects where smoking status was known, they were
either ex-smokers (n = 12) or current smokers (n = 9).
No association with NOS3 gene expression was observed
when all three genotypes were analyzed. However, as
shown in Figure 1, subjects with the AG + GG geno-
types combined demonstrated significantly lower NOS3
gene expression in comparison with the AA genotype
(p = 0.0366).
NOS3 protein levels in lung tissue
The same lung tissue samples used for NOS3 mRNA
expression were subsequently utilized for protein analysisparticipants in the LHS cohort and their associations
p-value*b N Mean ± SE Rate
of Decline in
FEV1 (% predicted)
p-value*a p-value*b
0.1424 2602 (79%) −0.97 ± 0.04 Referent 0.3530
635 (19%) −1.02 ± 0.07 0.5332
52 (2%) −1.27 ± 0.26 0.3434
0.1118 2705 (76%) −0.96 ± 0.03 Referent 0.1838
781 (22%) −1.03 ± 0.07 0.8221
81 (2%) −1.12 ± 0.20 0.4215
0.0018 1425 (41%) −1.05 ± 0.05 Referent 0.3838
1521 (44%) −0.92 ± 0.05 0.1149
504 (15%) −1.02 ± 0.07 0.7133
Table 5 Genetic association of NOS3 rs1800779 SNP with COPD affection status in each case–control study
Genotype COPDGene
β coefficient
(SE) p-value*
ECLIPSE
β coefficient
(SE) p-value*
NETT/NAS
β coefficient
(SE) p-value*
GenKOLS
β coefficient
(SE) p-value*
Meta-analysis
β coefficient
(SE) p-value*
AA Referent Referent Referent Referent Referent
AG 0.03 (0.15) 0.83 0.01 (0.19) 0.95 0.36 (0.19) 0.06 0.03 (0.13) 0.81 0.08 (0.08) 0.30
GG 0.15 (0.22) 0.49 0.13 (0.28) 0.6310 0.10 (0.27) 0.70 −0.05 (0.19) 0.79 0.07 (0.12) 0.57
*p values were adjusted for age, pack-years of cigarette smoking, and genetic ancestry.
Aminuddin et al. BMC Pulmonary Medicine 2013, 13:64 Page 5 of 10
http://www.biomedcentral.com/1471-2466/13/64by western blot. As shown in Figure 2, subjects with the
rs1800779 AG+GG genotypes combined demonstrated
significantly lower levels of NOS3 in comparison with
individuals who had the AA genotype (p = 0.0002). We
then used immunohistochemical analysis of lung tissue
from three randomly selected donors of each genotype to
localize NOS3 expression. As shown in Figure 3, the
staining demonstrated NOS3 protein expression predom-
inantly within the airway epithelium and again subjects
with AA genotype demonstrated higher NOS3 expression
compared with AG and GG individuals.
Discussion
In this study we investigated three polymorphisms in the
NOS genes in relation to cross-sectional lung function
and rate of decline of lung function in COPD patients.
Although we observed a significant association with
rs1800779 in NOS3 with baseline lung function in the
derivation cohort we were unable to replicate the associ-
ation in additional patient groups. Nevertheless, we were
able to demonstrate that the rs1800779 SNP has a func-
tional effect on the expression of the NOS3 gene and this
has implications for the numerous disease states that have
been associated with this polymorphism [24-27].
The NOS gene variants that we investigated were
limited to those that had strong a priori evidence for
involvement in regulation of gene expression or in a trait
related to COPD. We utilized this approach to maximize
power by limiting the number of comparisons that were
made. If a tag SNP approach had been used, a total of 137
polymorphisms would have had to be genotyped (using aTable 6 Genetic association of NOS3 rs1800779 SNP with FEV
Group Genotype COPDGene
β coefficient
(SE) p-value*
ECLIPSE
β coefficient
(SE) p-value*
Cases AA Referent Referent
AG 0.75 (1.84) 0.68 −1.43 (0.85) 0.09
GG 2.08 (2.60) 0.42 −0.52 (1.23) 0.67
Controls AA Referent Referent
AG 1.69 (1.10) 0.12 3.53 (2.35) 0.13
GG −0.73 (1.64) 0.66 0.36 (3.47) 0.92
*p values were adjusted for age, pack-years of cigarette smoking, and genetic anceminor allele cut off of 1 %, an r2 cut off for linkage
disequilibrium of 0.8 in the European population, and a
region 10 kb up- and downstream of each gene). Thus,
the correction for multiple comparisons would be sub-
stantially more severe and the power of the study greatly
reduced. The rationale for the SNP selection is described
below.
The NOS1 rs41279104 polymorphism that was selected
for this study was previously shown to be associated with
reduced gene expression [12]. The minor (T) allele was
associated with a 30 % reduction in expression in a
reporter gene assay [12]. The minor (A) allele of the
NOS2 rs8078340 polymorphism was associated with
considerably decreased affinity for nuclear protein(s)
[13] suggesting that it has functional significance. We
prioritized these polymorphisms for investigation in
this study, as we reasoned that these functional effects
could be relevant to a variety of traits, including COPD.
The rs1800779 polymorphism in NOS3 was associated
with COPD status and lower FEV1 % predicted in COPD
patients [14]. This is the only published report of a NOS
polymorphism associated with our disease of interest in
the Caucasian population.
The rs1800779 polymorphism has been previously
associated with a number of additional phenotypes but
only one of these traits, cytokine responses in children
at risk for asthma, was related to respiratory disease
[24]. rs1800779 is in strong LD (r2 > 0.8) with ten other
polymorphisms but none of these have been associated
with phenotypes related to lung function or pulmonary
disease.1 % predicted in each case–control study
NETT/NAS
β coefficient
(SE) p-value*
GenKOLS
β coefficient
(SE) p-value*
Meta-analysis
β coefficient
(SE) p-value*
Referent Referent Referent
−1.46 (0.84) 0.08 1.50 (1.30) 0.25 0.80 (0.52) 0.12
−1.42 (1.17) 0.23 −2.03 (2.04) 0.32 −0.88 (0.75) 0.24
Referent Referent Referent
−0.49 (1.37) 0.72 −0.98 (0.68) 0.15 −0.09 (0.52) 0.86
−1.62 (1.81) 0.37 −0.12 (1.05) 0.91 −0.51 (0.78) 0.51
stry.
Figure 1 The effect of rs1800779 on NOS3 mRNA expression in
lung tissue.
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respect to phenotypes related to COPD. Arif et al. [14]
studied four NOS3 polymorphisms in north Indian COPD
patients and controls: -786 T/C (rs3918161), -922A/G
(rs1800779), 894G/T (rs1799983), and the 4B/4A variable
number of tandem repeats (VNTR). rs3918161, rs1800779
and the VNTR were associated with COPD. However, data
from the HapMap project (http://hapmap.ncbi.nlm.nih.gov/)
show that rs3918161 is not polymorphic in individuals ofFigure 2 The effect of rs1800779 on NOS3 protein levels in lung tissu
tissue using 3 randomly selected subjects from each genotype. B) NOS3 pr
genotypic groups.European descent. It was not feasible to genotype the
VNTR with the large sample sizes in this study and
therefore rs1800779 was the only relevant polymorphism
in our study populations.
Ahsan et al. investigated NOS3 rs1799983 in 27 COPD
patients and 66 controls but there was no significant
difference (p = 0.18) in genotype frequency between the
groups [28]. An earlier study that examined the NOS3
VNTR did not find an association with COPD although
there was an association with pulmonary hypertension in
the patients [29]. Novoradovsky and colleagues genotyped
six NOS3 SNPs in patients with α1-antitrypsin deficiency
and found that rs1799983 and rs1549758 were increased
in severely affected cases compared with healthy controls
[30]. However, these associations were not confirmed by a
subsequent study of α1-antitrypsin deficient patients [31]
and none of our patients were α1-antitrypsin deficient.
NOS2 polymorphisms have been investigated in the context
of lung function growth and childhood asthma [32]. These
investigators included 24 SNPs in their analysis - seven of
which were in the NOS2 promoter. The haplotype block
including the promoter SNPs was associated with incident
asthma and impaired lung function growth during adoles-
cence. However, as the associations were seen in children
and were with asthma, the relevance to COPD, a disease
affecting an older demographic with a different pathology,
is not clear. Several studies have examined the relationshipe. A) Representative western blots of NOS3 protein levels in lung
otein levels normalized to β-tubulin in different rs1800779
Figure 3 NOS3 expression in the epithelium of lung tissue from
subjects stratified by rs1800779 genotype (NOS3 positive staining
denoted in brown).
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NO in asthmatics and/or healthy subjects but the results
have not been consistent [33-40] and therefore we did not
consider them in this study.
The NOS1 and NOS2 polymorphisms that we investi-
gated were both associated with functional effects on their
respective gene expression [12,13]. Therefore, we hypothe-
sized that these variants could be important factors in
COPD, and that an association of these variants with
FEV1 would be observed in smokers. However, we found
no significant associations between the NOS1 and NOS2
polymorphisms and lung function in COPD patients.
The rs1800779 polymorphism in the promoter of NOS3
was associated with lung function in the LHS participants.
This SNP was not in Hardy-Weinberg equilibrium;
however this could be due to several factors including
random chance, genotyping assay failure, population
stratification or because the SNP has a true genetic effect.
In this study, it is unlikely a genotyping assay failure oc-
curred since the positive controls were in 100% concord-
ance with genotypes from the HapMap database (n = 73).
The HapMap genotypes were generated with different
technologies than the one used in this study and therefore
the concordance is strongly indicative that the genotypes
are accurate. Furthermore, approximately 13% of the sub-
jects were re-genotyped and were in 100% concordance
with the initial genotype results (n = 573). In addition, the
LHS subjects were selected based on the presence ofmild/moderate COPD and therefore the testing for
Hardy-Weinberg equilibrium in this cohort may not be
appropriate.
The results of the study in the LHS cohort demon-
strated that the rs1800779 G allele was associated with a
higher baseline FEV1. Although we found an association
in the LHS we did not find any association of this SNP
with COPD in four case–control populations. This may
indicate that the association in the LHS is a false positive
result, even though a limited number of polymorphisms
were tested. Alternatively, the lack of replication may be a
reflection of the different recruitment strategies and hence
demographic factors in the cohorts involved e.g. the LHS
participants were younger and had less severe airflow
obstruction than the subjects in the other cohorts. The
data presented in this study are contradictory to results in
a previous paper which reported that the G allele of the
SNP is associated with reduced lung function in COPD
[14]. A reason for this discrepancy could be differences in
the study populations. The cohort used in the previous
study was composed of Indian subjects, whereas the cohort
in this study only included Caucasian subjects.
A follow-up experiment was performed to determine
the effect of the rs1800779 SNP on NOS3 gene expression
in lung tissue. It was observed that subjects who had the
AG + GG genotypes had lower NOS3 gene and protein
expression compared with the AA genotype. In addition,
immunohistochemical analysis demonstrated higher NOS3
expression in the airway epithelium of COPD patients with
the AA genotype. Taken together, these results strongly
suggest that the G allele is associated with decreased NOS3
expression.
The function of NO as a deleterious pro-inflammatory
or protective anti-inflammatory agent has yet to be fully
understood. However, there is evidence that NO is
implicated in the pathogenesis of lung diseases such
as COPD. NO is a radical molecule that can rapidly react
with superoxides, yielding a cytotoxic molecule known as
peroxynitrite. This compound has been shown to be an
important factor contributing to tissue damage in chronic
inflammation, as well as impairing key cellular functions
[41]. In particular, nitrosative stress mediated by perox-
ynitrite is evident in patients with COPD, suggesting the
toxic compound is a key contributor to the pathogenesis
of the disease [7]. Therefore, it can be speculated that
once exposed to an environmental pollutant, such as
cigarette smoke, airway cells and tissues experience oxi-
dative and nitrosative stress due to production of en-
dogenous NO.
Conclusions
Variants in the NOS genes were not associated with
lung function or COPD status. However, the G allele of
rs1800779 resulted in a decrease of NOS3 gene expression
Aminuddin et al. BMC Pulmonary Medicine 2013, 13:64 Page 8 of 10
http://www.biomedcentral.com/1471-2466/13/64and protein levels and this has implications for the
numerous disease states that have been associated with
this polymorphism. The rs1800779 polymorphism is also
an excellent candidate for traits that are influenced by
NO levels.
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